SGMT
Sagimet Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.09
−0.72%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.06
From 52W high−0.72%
Volume1.81M
Market cap$689.34M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$11.06
From 52W high
−0.72%
Volume
1.81M
Market cap
$689.34M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.1x
P/E (TTM)
—
RSI (14)
61.5
MomentumView details →
1D Return
−0.72%
YTD Return
+86.32%
SummaryUpdated Jun 1, 2026
Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Mateo, California. Originally incorporated as 3-V Biosciences, Inc., the company changed its name to Sagimet Biosciences in August 2019 and went public in July 2023. The company specializes in developing innovative therapeutics that target fatty acid synthase (FASN) inhibitors to treat diseases caused by dysfunctional lipid metabolism pathways, representing a novel approach in addressing metabolic disorders and certain cancers.
Similar companies
Latest newsMore news →
Sagimet Biosciences plans to begin a Phase III study of denifanstat for moderate-to-severe acne in the U.S. within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis.34d agoSagimet Biosciences received an FDA 'Study May Proceed' letter and IND clearance for its Phase 3 trial of denifanstat in moderate to severe acne in adolescent and adult patients in the U.S.38d agoSagimet Biosciences granted equity awards to President and CEO David Happel, CFO Thierry Chauche, and Chief Legal and Administrative Officer Elizabeth Rozek, effective May 28, 2026.110d ago